Biotech
🔥 Rejected Twice, Approved on the Third Try: The Tumor-Injected Virus That Just Cleared the FDA
After two rejections, Replimune's tumor-injected virus Tudriqev won accelerated FDA approval on August 6 — a 24.2% response rate in melanoma that had beaten standard immunotherapy.
